



medicines
patent
pool



Meds PaL

THE MEDICINES PATENTS AND LICENCES DATABASE

Update on publicly accessible databases of patent status information concerning medicines and vaccines, WIPO 31st SCP, Geneva, December 3, 2019

1. Introduction to the Medicines Patent Pool
2. Background on MedsPaL
3. How is patent data collected
4. Demonstration
5. Latest developments/Updates
6. Feedback / Use

Introduction to the Medicines Patent Pool

Created in 2010 as first voluntary licensing and patent pooling mechanism in public health

to increase access to new treatments for HIV through licensing of patented medicines

and **facilitate innovation**
e.g. new fixed dose combinations and paediatric formulations

In 2015, expanded mandate to Hepatitis C and Tuberculosis

In 2018, decision to expand to other patented essential medicines



MPP's activities in HIV, HCV and TB are funded by:



MPP's expansion into patented essential medicines is undertaken with financial support from:



Background on MedsPaL

April 2011

Launch of the MPP Patent Status Database, an enhanced worksheet including 24 HIV medicines in 88 countries

October 2016

Launch of MedsPaL as the most comprehensive source of information on the patent and licensing status of medicines for HIV, TB, hepatitis C and other patented essential medicines in low- and middle-income countries



The screenshot shows a web-based interface for the MPP Patent Status Database. It features a header with the Medicines Patent Pool logo and navigation tabs. Below the header is a table with multiple columns and rows, displaying patent information for various medicines across different countries. The table includes columns for medicine names, patent numbers, and countries.



MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

*Most comprehensive FREE source of information on the patent and licensing status of **patented essential medicines** in low- and middle-income countries.*

Patent status
data on more than

8000

**NATIONAL PATENT
APPLICATIONS**

from over 130 LMICs

Covering
approximately

100

**PRIORITY
MEDICINES**

(approx.
200 formulations)



With
information on

40

LICENCES

and other access
agreements
in LMICs

And data exclusivity
information from

15

COUNTRIES

www.medspal.org

Widely endorsed by public health organisations:



Patented medicines for the treatment of HIV, hepatitis C and tuberculosis that are (or were) included in WHO treatment guidelines

Patented medicines on WHO Essential Medicines list (EML)



Products in late stage development / Recent regulatory filings / Recommended treatment regimens



Possible future priority medicines as identified by WHO and other public health stakeholders

How is patent data collected

How is national/regional patent data obtained?

- USFDA Orange book 
- Health Canada patent register 
- Publicly available licences
- Published patent landscapes (e.g. by WHO or UNITAID)

1- Identification of basic/relevant patents

 Automated processes

Search for the INN Dolutegravir in Health Canada Patent Register



Government
of Canada

Gouvernement
du Canada

MENU ▾

[Home](#) > [Drugs & Health Products](#) > [Drug Products](#) > Patent Register

Search results for medicinal ingredient

From [Health Canada](#)







Search results for medicinal ingredient **DOLUTEGRAVIR SODIUM**

To view detailed patent and submission information select the link for the record you wish to view.


Filter items

Showing 1 to 3 of 3 entries | Show entries

Medicinal ingredient search results

Medicinal ingredient 	Brand name 	Strength 	Dosage 	DIN ¹ 	Patent 
dolutegravir sodium	TIVICAY	50 mg	tablet	02414945	2606282
dolutegravir sodium	TIVICAY	10 mg	tablet	02461218	2606282
dolutegravir sodium	TIVICAY	25 mg	tablet	02461226	2606282

Search for the INN Dolutegravir in US FDA Orange Book



Home > Drug Databases > Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[f SHARE](#)
[t TWEET](#)
[in LINKEDIN](#)
[p PIN IT](#)
[e EMAIL](#)
[p PRINT](#)

[Home](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that an NDA holder or patent owner.

Patent and Exclusivity for: N204790

Product 001
DOLUTEGRAVIR SODIUM (TIVICAY) TABLET EQ 50MG BASE

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission
001	8129385	10/05/2027	DS	DP			08/27/2013
001	9242986	12/08/2029	DS	DP			03/10/2016

1- Identification of basic/relevant patents


Patent data disclosed in publicly available licences e.g. MPP and ViiV Healthcare agreement on Dolutegravir

Appendix E, Part B: Non-Territory Patents in respect of the DTG Compound registered in countries which fall within Appendix C but do not fall within Appendix B (Territory):


Country	Application Number	Application Date	Patent Number
Albania	AL/P/2015/000276	24-Jan-2011	5403
Algeria	70738	28-Apr-2006	5531
	120523	24-Jan-2011	
Azerbaijan	200702080	28-Apr-2006	14162
	201290583	24-Jan-2011	
Belarus	200702080	28-Apr-2006	14162
	201290583	24-Jan-2011	
Bosnia and Herzegovina	11737484.3	24-Jan-2011	EP2531027
Brazil	PI0610030-9	28-Apr-2006	
	PI0923217-6	8-Dec-2009	
	BR1120120186701	24-Jan-2011	
Bulgaria	6758843.4	28-Apr-2006	1874117
	11737484.3	24-Jan-2011	EP2531027
China P.R.	2.00680022891.4	28-Apr-2006	ZL200680022891.4
	2.00980135216.6	23-Jul-2009	ZL200980135216.6
	201310734307.X	23-Jul-2009	ZL201310734307.X
	2.01510553862.2	2-Sep-2015	
	200980149670.7	9-Dec-2009	ZL200980149670.7
	201510071074.9	9-Dec-2009	
	200980149697.6	8-Dec-2009	ZL200980149697.6
	201180015114.8	24-Jan-2011	ZL201180015114.8
Colombia	07-115501	28-Apr-2006	1886
	12-125.933	24-Jan-2011	6085
Costa Rica	2012-423	24-Jan-2011	

How is national/regional patent data obtained?

2 -Collection of related patent family information

- INPADOC Patent family 
- WIPO Patentscope
- Patent holder disclosures (e.g. to national patent offices; Pat-Informed, MPP licences)

Search for equivalent patents/patent applications available in public databases such as Espacenet (European Patent Office):



Espacenet
Patent search

Deutsch English Français
Contact
Change country ▼

◀ About Espacenet Other EPO online services

Search Result list ★ My patents list (0) Query history Settings Help

Refine search → Results → CA2606282 (A1)

CA2606282 (A1)
Bibliographic data
Description
Claims
Mosaics
Original document
Cited documents
Citing documents
INPADOC legal status
INPADOC patent family

Quick help —

- [What is meant by high quality text as facsimile?](#)
- [What does A1, A2, A3 and B stand for after a European publication number?](#)
- [What happens if I click on "In my patents list"?](#)
- [What happens if I click on the "Register" button?](#)
- [Why are some sidebar options deactivated for certain documents?](#)
- [How can I bookmark this page?](#)
- [Why does a list of documents with the heading "Also published as" sometimes appear, and what are these documents?](#)
- [Why do I sometimes find the abstract of a corresponding document?](#)
- [What happens if I click on the red "patent translate" button?](#)
- [What is Global Dossier?](#)

Bibliographic data: CA2606282 (A1) — 2006-11-02

★ In my patents list Report data error Print

POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY

Page bookmark [CA2606282 \(A1\) - POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY](#)

Inventor(s): TAODA YOSHIYUKI [JP]; TAISHI TERUHIKO [JP]; KAWASUJI TAKASHI [JP]; JOHNS BRIAN ALVIN [US] ±

Applicant(s): SHIONOGI & CO [JP]; SMITHKLINE BEECHAM CORP [US] ±

Classification:

- international: [A01N43/58](#); [A01N43/60](#); [A61K31/495](#); [A61K31/50](#); [C07D239/00](#); [C07D241/36](#); [C07D471/00](#); [C07D487/00](#); [C07D495/00](#); [C07D497/00](#)
- cooperative: [A61K31/4985 \(EP, KR, NO, US\)](#); [A61K31/519 \(EP, US\)](#); [A61K31/5365 \(EP, US\)](#); [A61K31/551 \(EP, US\)](#); [A61K45/06 \(US\)](#); [A61K9/0053 \(US\)](#); [C07D471/04 \(EP, US\)](#); [C07D471/14 \(EP, NO, US\)](#); [C07D471/22 \(EP, US\)](#); [C07D498/04 \(EP, NO, US\)](#); [C07D498/14 \(EP, US\)](#); [C07D498/20 \(EP, US\)](#); [C07D498/22 \(EP, US\)](#)

Application number: CA 2006 2606282 20060428

Priority number(s): [JP20050131161 20050428](#) ; [JP20050312076 20051027](#) ; [WO2006US16604 20060428](#)

Also published as: [CA2606282 \(C\)](#) [AU2006239177 \(A1\)](#) [AU2006239177 \(B2\)](#) [AU2006239177 \(B8\)](#) → [BRPI0610030 \(A2\)](#) → [CY1115151 \(T1\)](#) → [CY1116331 \(T1\)](#) → [CY1120345 \(T1\)](#) → [DK1874117 \(T3\)](#) [DK2465580 \(T3\)](#) [DK3045206 \(T3\)](#) [DK3284520 \(T3\)](#) [EA014162 \(B1\)](#) [EA200702080 \(A1\)](#) → [EP1874117 \(A1\)](#) → [EP1874117 \(A4\)](#) → [EP1874117 \(B1\)](#) → [EP1874117 \(B8\)](#) [EP2465580 \(A1\)](#) [EP2465580 \(B1\)](#) [EP2527007 \(A1\)](#) [EP2527007 \(B1\)](#) [EP3045206 \(A1\)](#) [EP3045206 \(B1\)](#) [EP3187225 \(A1\)](#) [EP3187226 \(A1\)](#) [EP3284519 \(A1\)](#) [EP3284519 \(A8\)](#) [EP3284520 \(A1\)](#) [EP3284520 \(B1\)](#) [EP3372281 \(A1\)](#) [ES2437268 \(T3\)](#) [ES2446324 \(T3\)](#) [ES2567197 \(T3\)](#) [ES2667868 \(T3\)](#) → [HK1107227 \(A1\)](#) → [HK1172282 \(A1\)](#) [HUE037795 \(T2\)](#) → [HUS1400039 \(I1\)](#) [IL186555 \(A\)](#) → [IL225206 \(A\)](#) → [IL225207 \(A\)](#) [JP2008540343 \(A\)](#) [JP2009079058 \(A\)](#) [JP4295353 \(B2\)](#) [KR101363875 \(B1\)](#) [KR101504998 \(B1\)](#) [KR101580310 \(B1\)](#) [KR101848819 \(B1\)](#) → [KR20080009733 \(A\)](#) [KR20130133061 \(A\)](#) [KR20140097438 \(A\)](#) [KR20160003889 \(A\)](#) → [LT3045206 \(T\)](#) → [LT3284520 \(T\)](#) → [LU92446 \(I2\)](#) [MA29460 \(B1\)](#) → [MX2007013351 \(A\)](#) → [MX302718 \(B\)](#) → [MX312216 \(B\)](#) [NL300676 \(I2\)](#) → [NO20075165 \(L\)](#) [NO20161315 \(A1\)](#) → [NO2017010 \(I1\)](#) → [NO2017010 \(I2\)](#) [NO339525 \(B1\)](#) → [NO340111 \(B1\)](#) [NZ562339 \(A\)](#) → [PL3045206 \(T3\)](#) [PT1874117 \(E\)](#) [PT2465580 \(E\)](#) [PT3045206 \(T\)](#) [SI1874117 \(T1\)](#) [SI2465580 \(T1\)](#) [SI3045206 \(T1\)](#) [SI3284520 \(T1\)](#) [TW200716635 \(A\)](#) [TWI378931 \(B\)](#) [US2009318421 \(A1\)](#) [US2012115875 \(A1\)](#) [US2013172559 \(A1\)](#) [US2014200209 \(A1\)](#) [US2015232479 \(A1\)](#) [US2016137666 \(A1\)](#) [US2016207939 \(A1\)](#) [US2016304535 \(A1\)](#) [US2017029438 \(A1\)](#) [US2017145033 \(A1\)](#) [US2017209454 \(A1\)](#) [US2017224694 \(A1\)](#) [US2017224695 \(A1\)](#) [US2017253616 \(A1\)](#) [US2017260203 \(A1\)](#) [US2017267693 \(A1\)](#) [US2017369509 \(A1\)](#) [US2019152990 \(A1\)](#) [US2019284208 \(A1\)](#) [US8129385 \(B2\)](#) [US8410103 \(B2\)](#) [US8778943 \(B2\)](#) [US9051337 \(B2\)](#) [US9273065 \(B2\)](#) → [VN34404 \(A1\)](#) [WO2006116764 \(A1\)](#) → [less](#)

2 - Collection of related patent family information

Search for equivalent patents/patent applications in public databases such as Patentscope (WIPO)

PATENTSCOPE HEL


Search International and National Patent Collections

Q Search | Browse | Translate | News Try the new lo

← ↑ → Machine translation

1. (CA2606282) POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES HAVING HIV INTEGRASE INHIBITORY ACTIVITY

National Biblio. Data | Description | Claims | Documents

PermaLink 

Office : Canada


Application Number: 2606282 **Application Date:** 28.04.2006

Publication Number: 2606282 **Publication Date:** 02.11.2006

Grant Number: **Grant Date:** 26.04.2016

Publication Kind : C

Prior PCT appl.: Application Number:PCTUS2006016604 ; Publication Number: [Click to see the data](#)

IPC: C07D 471/22 
 A61K 31/4985
 A61K 31/519
 A61K 31/5365
 A61P 31/18
 C07D 471/14
 C07D 498/14


Applicants: SHIONOGI & CO., LTD.
 SMITHKLINE BEECHAM CORPORATION

Inventors:

Priority Data: 2005-131161 28.04.2005 JP
 2005-312076 27.10.2005 JP

Title: **(EN)** POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES HAVING HIV INTEGRASE INHIBITORY ACTIVITY
(FR) DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH

Abstract: **(EN)**
 Novel compounds of formula (I) shown below are provided, having anti-HIV activity, particularly HIV integrase inhibitory activity, as well as processes for their preparation and intermediates used therein, for potential use as anti-HIV drugs.
 (see formula I)
 (wherein
 Z1 is NR4;
 R1 is hydrogen or lower alkyl;
 X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH,
 or lower alkylene or lower alkenylene in which the hetero atom group may intervene;
 R2 is optionally substituted aryl;
 R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc;
 and
 R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.)



(I)

Also published as:

NO20075165	NO20161315	<u>UAa200711345</u>	MXMX/a/2007/013351	ZA2007/08970	KR1020080009733
IL186555	EP1874117	JP2008540343	IL215788	US20090318421	EP2465580
EP2527007	CN101212903	EA200702080	ES2437268	KR1020130133061	KR1020140097438
KR1020160003889	EP3045206	NZ562339	DK1874117	AU2006239177	EP3187225
EP3187226	VN17646	VN34404	<u>ID048.1260</u>	IL225206	IL225207
EP3284519	EP3284520	<u>WO/2006/116764</u>			

2 - Collection of related patent family information

Search for equivalent patents/patent applications in public databases such as Patentscope (WIPO) : National phase tab of the corresponding international application

Search International and National Patent Collections

Q Search | Browse | Translate | News

Try the new look

1. (WO2006116764) POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY



PCT Biblio. Data | Description | Claims | **National Phase** | Notices | Documents

Available information on National Phase entries(more information)

Office	Entry Date	National Number	National Status
China	28.04.2006	200680022891.4	
New Zealand	09.10.2007	562339	Published: 28.01.2011 Granted: 09.05.2011
Israel	10.10.2007	186555	Granted: 01.02.2017
India	10.10.2007	3865/KOLNP/2007	Published: 18.07.2008
South Africa	18.10.2007	2007/08970	
Canada	23.10.2007	2606282	
Eurasian Patent Organization	24.10.2007	200702080	Published: 28.04.2008 Granted: 29.10.2010
Australia	25.10.2007	2006239177	Published: 15.11.2007
Mexico	25.10.2007	MX/a/2007/013351	Published: 18.04.2008 Granted: 27.08.2012
Philippines	25.10.2007	12007502373	Granted: 25.03.2013
Japan	26.10.2007	2008509227	
European Patent Office	30.10.2007	2006758843	Published: 09.01.2008 Granted: 28.08.2013
Colombia	31.10.2007	07115501	Published: 30.05.2008 Granted: 26.01.2012
Colombia	31.10.2007	07115501A	Granted: 15.06.2012
Norway	22.11.2007	20075165	
Republic of Korea	28.11.2007	1020077027734	Refused: 29.07.2013 Granted: 28.11.2013
Ukraine	28.11.2007	a200711345	Published: 10.04.2008 Granted: 25.11.2011
United States of America	28.07.2009	11919386	Published: 24.12.2009 Granted: 06.03.2012
Israel	23.10.2011	215788	
Israel	14.03.2013	225207	
Israel	14.03.2013	225206	Granted: 01.03.2018
Republic of Korea	23.06.2014	1020147017235	Granted: 18.09.2015
Republic of Korea	18.12.2015	1020157036007	
Germany			Withdrawn: 30.10.2007
European Patent Office		2012159079	Granted: 30.03.2016
European Patent Office		2017156763	Published: 05.07.2017
European Patent Office		2012159082	Granted: 18.12.2013
European Patent Office		2017195276	Divisional: 06.10.2017
European Patent Office		2017156762	Published: 05.07.2017
European Patent Office		2017195280	Divisional: 06.10.2017
European Patent Office		2016154531	Published: 20.07.2016
Norway		20161315	Divisional: 18.08.2016
Russian Federation			Withdrawn: 28.11.2007



2 - Collection of related patent family information

Patent holder disclosures e.g. to patent offices

Controller General of Patents, Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

Application Details	
APPLICATION NUMBER	3865/KOLNP/2007
APPLICATION TYPE	PCT NATIONAL PHASE APPLICATION
DATE OF FILING	10/10/2007
APPLICANT NAME	VIIV HEALTHCARE COMPANY
TITLE OF INVENTION	POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
FIELD OF INVENTION	PHARMACEUTICALS
E-MAIL (As Per Record)	email@anandandanand.com
ADDITIONAL-EMAIL (As Per Record)	
E-MAIL (UPDATED Online)	
PCT INTERNATIONAL APPLICATION NUMBER	PCT/US2006/016604
PCT INTERNATIONAL FILING DATE	28/04/2006
PRIORITY DATE	28/04/2005
REQUEST FOR EXAMINATION DATE	22/04/2009
PUBLICATION DATE (U/S 11A)	18/07/2008
FIRST EXAMINATION REPORT DATE	27/02/2012
REPLY TO FER DATE	04/03/2016

Controller General of Patents, Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

Application Status	
APPLICATION STATUS	Application in Amended stage

View Examination Report(s)
Order(s)/Decision(s)
View Documents




Controller General of Patents, Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

Document Name	Created Date/Uploaded Date
3865-KOLNP-2007-FORM 3 [23-07-2019(online)].pdf	23/07/2019
3865-KOLNP-2007-Written submissions and relevant documents (MANDATORY) [02-05-2019(online)].pdf	02/05/2019
3865-KOLNP-2007-Statement and Evidence (MANDATORY) [25-04-2019(online)].pdf	25/04/2019

NO	OFFICE	APPL NO	STATUS	DATE	DATE	DATE	DATE	DATE	DATE	DATE
50										
51	Algeria	070738	Patented	None	None	5531	No	28-04-2006	12-05-2010	granted
52										
53	Australia	2006239177	Patented	None	None	2006239177	No	28-04-2006	02-02-2012	granted
54										



	A	B	C	D	E	F	G	H	I	J	K
55			Litigation Analysis - Phillips Ormonde								
56											
57	Brazil	PI 0610030-9	Pending	None	None	None	No	28-04-2006			opposition pending
58											
59	Opposition 1	BLANVER	Pending								
60											
61	Canada	2606282	Patented	None	None	2606282	Yes After File Request	28-04-2006		26-04-2016	granted
62											
63											
64											
65	China	200680022891.4	Patented	None	None	ZL200680022891.4	No	28-04-2006	101212903	24-07-2013	granted
66											
67	Columbia	07-115.501	Patented	None	None	1886	No	28-04-2006	592	16-04-2012	granted
68											
69	Columbia DIV	07-115.501A	Patented	None	None	1887	No	28-04-2006		05-07-2012	granted
70											
71	Egypt	PCT 1167/2007	Pending	None	None	None	Yes	28-04-2006			under examination
72											

Patent holder disclosures e.g. in Pat-INFORMED



Search bar: Country:

[Display all INNs](#)

INN	Participant	Patents
Abacavir Sulfate, Dolutegravir, Lamivudine		SYNERGISTIC COMBINATIONS OF ZIDOVUDINE, 1592U89 AND 3TC OR FTC
		SYNTHESIS OF CARBAMOYL PYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES
		POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
		CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL INFECTIONS
		ANTIVIRAL THERAPY
Dolutegravir, Rilpivirine Hydrochloride		SYNTHESIS OF CARBAMOYL PYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES
		POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
		ANTIVIRAL THERAPY
Dolutegravir		SYNTHESIS OF CARBAMOYL PYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES
		POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

Close card

POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

Participant: 

In order to contact GlaxoSmithKline about this patent you need to [log in](#) or [create an account](#).

The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted

DISCLAIMER: Pat-INFORMED is not intended as a replacement for a freedom-to-operate analysis, is not free of errors, and should not be relied upon as a comprehensive inventory of patent information. Pending applications are not listed, and in certain cases licensing arrangements or other factors may prevent Participants from listing patents. Use of Pat-INFORMED is subject to its [Term of Use and Disclaimers](#)

<p>(Country not covered by PATENTSCOPE.)</p> <p>Jurisdiction SK - Slovakia Publication number EP3045206 Publication date 2016/07/20 (3 years ago) Filing date 2016/02/05 (4 years ago) Grant date 2018/03/28 (2 years ago) Grant number EP3045206</p> <p>(Country not covered by PATENTSCOPE.)</p>	<p>(Country not covered by PATENTSCOPE.)</p> <p>Jurisdiction SK - Slovakia Filing date 2014/07/02 (5 years ago) Grant date 2015/11/06 (4 years ago) Grant number D0202</p> <p>Relates to extended exclusivity (Country not covered by PATENTSCOPE.)</p>
<p>(Country not covered by PATENTSCOPE.)</p> <p>Jurisdiction TJ - Tajikistan Filing date 2006/04/28 (14 years ago) Grant date 2010/10/29 (9 years ago) Grant number 14162</p> <p>(Country not covered by PATENTSCOPE.)</p>	<p>(Country not covered by PATENTSCOPE.)</p> <p>Jurisdiction TM - Turkmenistan Filing date 2006/04/28 (14 years ago) Grant date 2010/10/29 (9 years ago) Grant number 14162</p> <p>(Country not covered by PATENTSCOPE.)</p>
<p>(Country not covered by PATENTSCOPE.)</p> <p>Jurisdiction TR - Turkey Publication number EP1874117 Publication date 2008/01/09 (12 years ago) Filing date 2006/04/28 (14 years ago) Grant date 2013/08/28 (6 years ago) Grant number 2013/11091</p> <p>(Country not covered by PATENTSCOPE.)</p>	<p>(Country not covered by PATENTSCOPE.)</p> <p>Jurisdiction TR - Turkey Publication number EP3045206 Publication date 2016/07/20 (3 years ago) Filing date 2016/02/05 (4 years ago) Grant date 2018/03/28 (2 years ago) Grant number EP3045206</p> <p>(Country not covered by PATENTSCOPE.)</p>

How is national/regional patent data obtained?

- Online national and regional PO registers
- National patent collections on WIPO PatentScope
- INPADOC Legal Status data 
- Direct communications with patent offices, local experts
- MOUs with patent offices

3 - Status check & updates



Automated processes

National Patent Registers e.g. China



中国专利公布公告

首页 高级查询 IPC分类查询 LOC分类查询 事务数据查询 数据说明

公布公告查询

发明公布 发明授权 实用新型 外观设计 [使用说明](#)

类型选择 公布模式 列表模式 附图模式 每页显示3条记录

排序方式

- » 发明公布
- » 发明授权
- » 按申请日升序排序
- » 按申请日降序排序
- » 按公布公告日升序排序
- » 按公布公告日降序排序

【发明公布】具有HIV整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物

申请公布号: CN101212903

申请号: 2006800228914

申请公布日: 2008.07.02

申请日: 2006.04.28

申请人: 史密丝克莱恩比彻姆公司; 盐野义制药株式会社

发明人: B-A.约翰斯

地址: 美国宾夕法尼亚州

分类号: A01N43/58(2006.01); 全部

摘要: 本发明提供新的如下所示的化合物(I), 其具有抗 - 病毒活性, 特别是HIV整合酶抑制活性, 及含有相同化合物的药物, 特别是抗 - HIV药物, 以及其制备方法和中间体。化合物(I), 其中Z¹为 NR⁴; R¹为氢或低级烷基; X为单键、选自O、S、SO、SO₂和NH的杂原子基团, 或低级亚烷基或 全部

[【发明专利】](#) [【发明专利申请】](#) [【事务数据】](#)



中国专利公布公告

首页 高级查询 IPC分类查询 LOC分类查询 **事务数据查询** 数据说明

发明专利

发明专利申请

事务数据

具有HIV整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物

申请(专利)号	2006800228914	事务数据类型	专利权人的姓名或者名称、地址的变更
事务数据公告日	2013.07.31		

专利权人的姓名或者名称、地址的变更

IPC(主分类):A01N43/58

变更事项:专利权人

变更前:史密丝克莱恩比彻姆公司

变更后:葛兰素史密丝克莱恩有限责任公司

变更事项:地址

变更前:美国宾夕法尼亚州

变更后:美国宾夕法尼亚州

变更事项:专利权人

变更前:盐野义制药株式会社

变更后:盐野义制药株式会社

Polycyclic carbamoyl pyridone derivative having HIV integrase inhibitory activity

Application (patent) number	2006800228914	Transaction data announcement day	2013.07.31	Transaction data type	Change of name or address of patentee
-----------------------------	---------------	-----------------------------------	------------	-----------------------	---------------------------------------

Change of the name or address of the patentee

IPC (Main Category): A01N43/58

Change : Before the change of the patentee : Smith Klein Bicham Company

changed: GlaxoSmithKline Klein limited liability

Change of company :

Before the change of address :

After the change of Pennsylvania, USA : Change of Pennsylvania, USA

:

Before the change of patentee :

After the change of Yanyeyi Pharmaceutical Co., Ltd.: Yanyeyi Pharmaceutical Co., Ltd.

National Patent Registers e.g. Vietnam

IP Lib NATIONAL OFFICE OF INTELLECTUAL PROPERTY OF VIETNAM
Industrial Property Digital Library (IP LIB)

Mon, 11/11/2019

English Vietnamese

Found : 1 record(s) [Last Query](#) [Extended](#)
Hits 1 through 1 out of 1

[Previous](#) Page: 1 [Next](#)

Application No = 1200702531

<input type="checkbox"/> Check All	Title of invention
<input type="checkbox"/> 1.	Hợp chất carbamoylpyridon đa vòng có hoạt tính ức chế integraza của HIV và dược phẩm chứa hợp chất này.

[Clear Select](#) [Refine Result](#) View: [Compact](#)

Registration Number	1-0012249-000
Registration Date	07/01/2014
IPC Class	(51) ⁷ IPC A01N 43/58, A01N 43/60, A61K 31/495, A61K 31/50, C07D 239/00, C07D 241/36, C07D 471/00, C07D 487/00, C07D 495/00, C07D 497/00
Application Number	1-2007-02531 (22)
PCT Number	PCT/US06/016604 (87)
Priority Number	2005-312076 27/10/2005 JP 2005-131161 28/04/2005 JP
PubB Date	25/02/2014 311 (43)
Right Holder Name	SHIONOGI & CO., LTD. (JP) 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-0045, Japan

Bibliographic	Description	Claims	Drawings	Legal status
1-2007-02531 -Legal status				
Expire Date	28/04/2026	Chukan Code		
(30/06/2008) 221: Notification for Acceptance of Application (30/10/2013) 210: Notificaion on Amendment of Application's Assignment (05/07/2013) 111: Request for Assignment of Application (18/03/2008) 123: Response to Notification on Formality Checking Results (06/10/2008) 141: Request for Substantive Examination (28/12/2012) 143: Request for Notificaion on Substantive Examination Results (28/12/2012) 143: Request for Notificaion on Substantive Examination Results (21/12/2009) 143: Request for Notificaion on Substantive Examination Results (29/10/2013) 151: Registration and Publication Fee Receipt (10/12/2007) 157: Submission the Power of Attorney (Original) (30/10/2012) 186: Request for Extension of Time for Response (06/10/2008) 190: Submission of Other Documents (30/10/2013) 211: Notification on Certification for Assignment of Application (04/07/2013) 100: Amendment/Additional Material for Application (31/08/2012) 241: Notification on Substantive Examination Result (Conditional Grant) (22/10/2009) 241: Notification on Substantive Examination Result (Conditional Grant) (22/10/2013) 252: Notification on Grant (after response) (18/02/2008) 225: Thông báo dự định từ chối				

Regional

African
Regional IP
Organisation



Eurasian Patent Office



European Patent Office



National



Argentina



Brazil



Chile



Dominican Republic



Ecuador



Egypt



Peru



Companies and Intellectual
Property Commission
a member of the dti group

South Africa




Uruguay



El Salvador

13 patent offices have signed MoUs with the MPP committing to share data

How is national/regional patent data obtained?



Demonstration

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries. For more detailed and up-to-date information on a given patent application, MedsPaL users are encouraged to contact the national patent office or consult legal counsel.

[Additional information and disclaimer](#)

SEARCH VIEW


MAP VIEW


Keyword Search





Products

Countries

Add/Remove Columns 

Export Patent Data 

Share This Search 

Clear Search 

Search by keywords across all fields (e.g. patent number; brand name; country, etc.)

Pre-determined search by Products (e.g. Abacavir 300mg)


Search by Countries (e.g. Chile, South Africa, Vietnam)

SEARCH VIEW MAP VIEW

Keyword Search x Dolutegravir 50 mg P x Ukraine x Vietnam

[Add/Remove Columns](#) [Export Patent Data](#) [Share This Search](#) [Clear Search](#)

Showing result 1 out of 1 total results


Country	Product Name(s)	Patent Description	Patent Status	Patent Application Date (dd/mm/yyyy)	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 Ukraine	Dolutegravir 50 mg In EML	Dolutegravir and Cabotegravir compounds	Term extended	28/04/2006	UAA200711345	28/04/2026

Data Exclusivity:
Test data exclusivity until 29/12/2019

Data exclusivity

Patent/Patent application information

Licence(s):
MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
MPP licence on paediatric formulations of dolutegravir (DTG)

 Vietnam	Dolutegravir 50 mg In EML	Dolutegravir and Cabotegravir compounds	Granted	28/04/2006	VN201300151	28/04/2026
		Dolutegravir and Cabotegravir compounds	Granted	28/11/2007	VN1200702531	28/04/2026

Licence(s):
MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
MPP licence on paediatric formulations of dolutegravir (DTG)

Licence information

✕

Patent Card

Country: Ukraine

Patent Application Number: UAA200711345

Patent Status: Term extended

Patent Application Date (dd/mm/yyyy): 28/04/2006

Expected Expiry Date (dd/mm/yyyy): 28/04/2026

Patent Description: Dolutegravir and Cabotegravir compounds

Invention Title: Polycyclic Carbamoyl Pyridone Derivative As Hiv Integrase Inhibitor

Patent Family Identification: US FDA, Health Canada

Publication / Grant Number(s): UA96568C2 [Link to Espacenet](#)

Priority Number(s): JP2005131161

Patent Applicant(s): Glaxosmithkline Llc, Shionogi & Co., Ltd

PCT Related Application(s): [WO2006088173A1](#)
[WO2006116764A1](#)
[WO2007049675A1](#)

Patent Status Source: Applicant

Last Updated (dd/mm/yyyy): 11/09/2019

Print 
Copy Link 
Close

Country	Product Name(s)	Patent	Expected Expiry Date (dd/mm/yyyy)	Last Updated On (dd/mm/yyyy)
Ukraine	Dolutegravir 50 mg In EML	Dolutegravir	28/04/2026	11/09/2019
Vietnam	Dolutegravir 50 mg In EML	Dolutegravir	28/04/2026	24/09/2018
		Dolutegravir	28/04/2026	23/03/2016

Licence Card ✕

Link to MPP website



Title: MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

Type: MPP Licence

Licensor: ViiV

Countries: Afghanistan, Angola, Armenia, Bangladesh, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi [Show 84 more](#)

Licensee(s): Anhui, Celltrion, Cipla, Desano, Dr. Reddy, Emcure, Hetero, Huahai, Langhua, Laurus Labs [Show 7 more](#)

Print 
Copy Link 
Close

https://medicinespatentpool.org/licence-post/dolutegravir-adul

DOLUTEGRAVIR – ADULT (DTG)

COMPANY: ViiV HEALTHCARE
DATE: APRIL 2014



In April 2014, the MPP and ViiV Healthcare announced two licensing agreements to accelerate access to dolutegravir (DTG), a promising new antiretroviral, for both adult and paediatric care. To date, the agreements allow generic manufacturers to produce low-cost versions of DTG for **at least 94 countries** for the adult agreement and **121 countries** for the [paediatric agreement](#).

The two parties extended the adult licence to cover all remaining lower middle-income countries in April 2016. The amendment specifically benefits four countries with patents – Armenia, Moldova, Morocco and Ukraine – that were not included in the initial 2014 agreement. As a result, countries that together are home to 94% of adults and 99%^[1] of children living with HIV in low- and middle-income countries, are covered by the licence.

An extension of the agreement for adults was signed in July 2018 to include Mongolia and Tunisia.

^[1]Coverage rates at time of announcement. Current coverage rates based latest UNAIDS data and on World Bank reclassification of countries is 90.3% (adults) and 98.2% (children).

 – LICENCE AGREEMENT
– SECOND AMENDED AND RESTATED LICENCE AGREEMENT

 – SUBLICENCE AGREEMENT - FORM


KEY
FEATURES


PRESS
RELEASE


CHAIRMAN'S
SUMMARY


ADVISORY GROUP
REPORT


COUNTRY
LIST


ADDITIONAL
INFORMATION

SEARCH VIEW
MAP VIEW


Select product 1

Select a product to display related patent or licence information per country directly on the map.

Dolutegravir 50 mg

Share This Search

Clear Search



Mongolia

- only in MPP licence on paediatric formulations of dolutegravir (DTG)
- in all licences for this product

Highlight countries 2

- With at least one patent granted/filed
- With at least one compound patent granted/filed
- Included in licence(s)

Select information to display in the map

Licences 3

- MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
- MPP licence on paediatric formulations of dolutegravir (DTG)

Select country on the map to display details

Latest developments/Updates

In October 2019, the MPP included 18 small molecules that were recently added to the WHO Model List of Essential Medicines to MedsPaL

Medicines (INN)	Indications
ceftazidime+avibactam meropenem+vaborbactam plazomicin	Antibiotics
apixaban dabigatran edoxaban rivaroxaban	Atrial fibrillation
tiotropium	Chronic obstructive pulmonary disease
telmisartan+amlodipine	Hypertension
telmisartan + hydrochlorothiazide	Hypertension
afatinib erlotinib, gefitinib	Lung cancer
bortezomib lenalidomide	Multiple myeloma
aprepitant	Nausea
carbetocin (heat-stable formulation)	Post-partum haemorrhage
abiraterone	Prostate cancer

Products in late stage development / Recent regulatory filings / Recommended treatment regimens

Medicines (INN)	Indications
Rifapentine (RPT)/Isoniazid (INH)	Latent tuberculosis infection
Bedaquiline+Pretomanid+Linezolid	Highly treatment-resistant tuberculosis
Cabotegravir	HIV (NDA submitted to the US FDA in 2019)

Licence Card ✕

Title: Bilateral Licence on Delamanid (Mylan)

Type: Bilateral Licence

Licensor: Otsuka

Countries: Afghanistan, Albania, Algeria, Angola, Bangladesh, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina
[Show 106 more](#)

Licensee(s): Mylan

Licence Card

Title: Bilateral Licence on Delamanid (R-Pharm)

Type: Bilateral Licence

Licensor: Otsuka

Countries: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyz Republic, Moldova, Republic of, Russian Federation, Tajikistan, Turkmenistan, Ukraine [Show 1 more](#)

Licensee(s): R-Pharm

Licence Card

Title:	Bilateral Licence on BDQ
Type:	Bilateral Licence
Licensor:	Janssen
Countries:	Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyz Republic, Moldova, Republic of, Russian Federation, Tajikistan, Turkmenistan Show 2 more
Licensee(s):	Pharmstandard

Licence Card ✕


Title:	TB Alliance/Mylan licence on pretomanid for use in the BPaL and BPaMZ regimens
Type:	Bilateral Licence
Licensor:	TB Alliance
Countries:	Afghanistan, Albania, Algeria, American Samoa, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Aruba Show 204 more
Licensee(s):	Mylan

Licence Card

Title:	TB Alliance/Macleods non-exclusive licence on pretomanid for use in the BPaL regimen
Type:	Bilateral Licence
Licensor:	TB Alliance
Countries:	Afghanistan, Albania, Algeria, American Samoa, Angola, Argentina, Armenia, Azerbaijan, Bangladesh, Belarus Show 133 more
Licensee(s):	Macleods

Medicines and formulations that are listed in the EML are now flagged as follows:

- 1 - in the products search box drop-down list with a flag (1)
- 2 - in the results list with a flag and the mention “In EML” (2)



The screenshot displays the search interface with the following elements:

- SEARCH VIEW** and **MAP VIEW** tabs at the top.
- Keyword Search** input field with a help icon.
- Products** dropdown menu showing search results:
 - Bendamustine 25 mg/ml
 - Bendamustine 45 mg/0,5mL** (highlighted with a red box and a red '1')
 - Bevacizumab 25 mg/ml** (highlighted with a red box and a red '1')
 - Bictegravir/Tenofovir alafenamide/Emtricitabine 50/25/200 mg
- Search** and **Clear Search** buttons.
- Country** and **Product Name(s)** columns in the results table.
- Results for **Afghanistan**:
 - Abacavir 300 mg **In EML** (highlighted with a red box and a red '2')
 - Licence(s): Bilateral licences for Sub-Saharan Africa, low-income countries and Least Developed Countries
 - Abacavir 20 mg/ml (Abacavir compound)
 - Abacavir 60 mg **In EML**
 - Licence(s): Bilateral licences for Sub-Saharan Africa, low-income countries and Least Developed Countries; MPP licence on paediatric formulations of abacavir (ABC)

The "last updated on" information corresponds to the date when the most recent legal event was added to the application or the date when the patent status was confirmed.


Add/Remove Columns ✕

- Patent Application Date (dd/mm/yyyy)
- Patent Application Number
- Publication / Grant Number(s)
- Expected Expiry Date (dd/mm/yyyy)
- Last Updated On (dd/mm/yyyy)
- Priority Number(s)
- PCT Related Application(s)

Keyword Search ? x Afatinib 20 mg P x India

Add/Remove Columns ⚙
Export Patent Data ↓
Share This Search 🔗
Clear Search ✕

Showing result 1 out of 1

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)	Last Updated On (dd/mm/yyyy)
	India Afatinib 20 mg In EML	Afatinib compound	Granted	IN00822/DELNP/2003	12/12/2021	17/10/2019
		Afatinib dimaleate crystalline forms and processes	Granted	IN2029/DELNP/2006	12/10/2024	17/10/2019
		Afatinib dimaleate salt compositions - compacted intermediates	Withdrawn	IN8598/DELNP/2010		20/08/2019

« 1 »

Regional

African
Regional IP
Organisation



Eurasian Patent Office



European Patent Office



National



Argentina



Brazil



Chile



Dominican Republic



Ecuador



Egypt



Peru



Companies and Intellectual
Property Commission
a member of the dti group

South Africa



Uruguay




El Salvador

13 patent offices have signed MoUs with the MPP committing to share data

- Complement patent data with **data exclusivity** data for the new additions
- Add some of the **biologics** that were recently added to the WHO EML and some of the WHO-recommended **vaccines**
- Consider implementing some of the recommendations made during recent **User Survey** (e.g. user alerts for specific products/patents? Direct links to national patent offices?)
- Explore ways to **better classify pharmaceutical patents**, in a manner to better guide users on the likely strength and relevance of specific patents or patent families


Feedback / Use


N: 85 Q5: What do you use it for? (You can select more than one option)



Follow-up interviews with 7 procurement agencies to gain further insights on how it's used and how it could be improved

N: 85 Q7: What information are you most interested in? (You can select more than one option)





Source: Google analytics, period from 1.10.2016 - 1.12.2019

*MedsPaL should not be considered a complete and authoritative source of patent information **and is not meant to provide a ‘freedom-to-operate’ analysis.** It only provides a snapshot at a particular point in time, based on the information that was available to the Medicines Patent Pool*

*Interested users are advised to **contact the relevant national/regional patent office, or to consult local patent counsel,** to obtain up to date information on any given patent application identified in MedsPaL*

*Users are also invited to submit information on any data that requires updating to the MPP at **medspal@medicinespatentpool.org***

MPP's HIV, TB and hepatitis C
activities are funded by:



**MPP'S EXPANSION INTO PATENTED ESSENTIAL MEDICINES
IS UNDERTAKEN WITH FINANCIAL SUPPORT FROM:**





THANK YOU

@MEDSPATENTPOOL

WWW.MEDICINESPATENTPOOL.ORG

WWW.MEDSPAL.ORG

eburrone@medicinespatentpool.org

amaillard@medicinespatentpool.org